复星医药 (600196)
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
K-Line Chart
No K-line data available
Company NameShanghai Fosun Pharmaceutical (Group) Co., Ltd.
Listing Date1998-08-07
Issue Price7.15RMB
Registered Capital267042.932510k RMB
Legal RepresentativeChen Yuqing
Registered Address9th Floor, No. 510 Cao Yang Road, Shanghai
IndustryChemical Pharmaceuticals
Main BusinessPharmaceutical manufacturing, pharmaceutical sales, medical devices and medical diagnostic products, etc.
Company ProfileShanghai Fosun Pharmaceutical (Group) Co., Ltd. (referred to as "Fosun Pharma", stock codes: 600196.SH, 02196.HK) was founded in 1994 and is a leading healthcare industry group in China. Fosun Pharma Group is committed to promoting human health, with its business covering the entire healthcare industry chain, including pharmaceutical manufacturing and R&D, medical services, medical devices and diagnostics, pharmaceutical distribution, and retail. Among these, pharmaceutical manufacturing and R&D form the core, while medical services are a key development focus.
Fosun Pharma Group regards innovative R&D as the most critical driving force for its development. It has established operations in China, the United States, India, and other locations, building efficient platforms for innovative chemical drugs, biologics, high-value generic drugs, and cell immunotherapy. Currently, Fosun Pharma's R&D efforts continue to focus on therapeutic areas such as oncology, cardiovascular diseases, central nervous system disorders, hematological diseases, metabolic and digestive system diseases, and anti-infectives. Its major products hold leading positions in their respective market segments.
Stock Details
1. Key Indicators
- Total Shares(W): 267042.93
- Circulating A-Shares(W): 211848.88
- Earnings Per Share(RMB): 0.9500
- Net Assets Per Share(RMB): 17.9853
- Operating Revenue(W RMB): 2939338.54
- Total Profit(W RMB): 383734.35
- **Net Profit Attributable to Parent(W RMB) **: 252329.35
- Net Profit Growth Rate(%): 25.50
- Weighted Return on Equity(%): 5.3000
- Operating Cash Flow Per Share(RMB): 1.2660
- Undistributed Profit Per Share(RMB): 10.5728
- Capital Reserve Per Share(RMB): 6.1172
2. Main Business
The main business covers:
- Pharmaceutical manufacturing
- Pharmaceutical sales
- Medical devices and medical diagnostic products
3. Company Basic Information
- Company Name: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
- Listing Date: 1998-08-07
- Industry: Pharmaceutical manufacturing
- Address: Building A, 1289 Yishan Road, Shanghai
- Website: https://www.fosunpharma.com/
- Company Profile: The company's predecessor was Shanghai Fosun Industrial Co., Ltd., which was restructured into a joint stock company on July 13, 1998. The promoters contributed their net assets to form 100.70 million promoter shares. After issuing 45 million public shares on June 15, 1998, the total share capital at listing reached 150.70 million shares. The 5 million internal employee shares were listed for trading on the Shanghai Stock Exchange on August 7, 1998, six months after the 45 million public shares were listed.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Shanghai Fosun High Technology (Group) Co., Ltd. | General Legal Person | 88989.10 | 42.01 |
| 2 | Hong Kong Securities Clearing Company Ltd. | Northbound Capital | 5524.54 | 2.61 |
| 3 | China Securities Finance Co., Ltd. | Special Legal Person | 3873.61 | 1.83 |
| 4 | Huatai-Pinebridge CSI 300 ETF | Fund | 2170.84 | 1.02 |
| 5 | China Merchants China Securities Bio-medicine Index (LOF) Fund Class A | Fund | 1818.55 | 0.86 |
| 6 | E Fund CSI 300 Healthcare ETF | Fund | 1592.71 | 0.75 |
| 7 | E Fund CSI 300 ETF | Fund | 1564.28 | 0.74 |
| 8 | Yinhua CSI Innovative Drug Industry ETF | Fund | 1241.14 | 0.59 |
| 9 | Tianhong China Securities Bio-medicine ETF | Fund | 638.24 | 0.30 |
| 10 | GF China Securities Innovative Drug Industry ETF | Fund | 606.50 | 0.29 |
5. Concept Sectors
- H-Share
- Biological Vaccine
- Private Hospital
- Intelligent Machinery
- Gene Concept
- Immunotherapy
- Intelligent Healthcare
- Generic Drugs
- Medical Aesthetics Concept
- CXO Concept
- Assisted Reproduction
- Family Doctor
- Innovative Drugs
- Weight Loss Drugs
- AI Agent
- DeepSeek
- AI Healthcare
Remarks
- Data update date: 2025-11-02
- Data source: Public market information